DOCSLIB.ORG

October 7 (Friday) October 7 the 75Th Annual Meeting of the Japanese Cancer Association Cancer Japanese of the Meeting Annual the 75Th Room 4 Oct

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
October 7 (Friday) October 7 the 75Th Annual Meeting of the Japanese Cancer Association Cancer Japanese of the Meeting Annual the 75Th Room 4 Oct INFORMATION The 75th Annual Meeting of the Japanese Cancer Association DAY 1 AM PM Day 2 LS October 7 (Friday) Posters DAY 2 AM LS PM Posters DAY 3 AM PM Posters LS INDEX Authors Keywords Chairpersons 125 Room 4 Oct. 7 (Fri.) 8:00-8:50 E Room 8 Oct. 7 (Fri.) 8:00-8:50 J Potential cancer therapeutics targeting TGF-β/Smad3 From Real-time Tumor-Tracking Technology to Motion ML1 signaling ML5 Science in Life 動体追跡技術から生体の動きの科学へ Chairperson: Susumu Itoh (BioChem., Showa Pharm. Univ.) 座長：伊東 進（昭和薬大・生命薬学・生化学） Chairperson: Masahiko Miura (Tokyo Med. & Dent. Univ.) 座長：三浦 雅彦（東京医歯大・院医歯・口腔放射線腫瘍） ML1 Potential cancer therapeutics targeting TGF-β/Smad3 signaling ML5 From Real-time Tumor-Tracking Technology to Motion Seong-Jin Kim1, Eunjin Bae1, Jinah Park1, Mi-Kyung Kwak1, Kazuhito Science in Life Naka2, Ooshima Akira1 (1Nanobio Med. Res. Ctr., AICT, Seoul Natl. Hiroki Shirato1,2 (1Dept. Radiat. Med., Grad. Sch. Med. Hokkaido Univ., Univ., 2Res. Inst. for Radiation Biol. & Med., Hiroshima Univ.) 2Quant. Med. Sci. Eng., Glob. Inst. Res. Ed., Hokkaido Univ.) 動体追跡技術から生体の動きの科学へ 白土 博樹 1,2（1 北海道大・医・放医、2 北海道大・国際連携・量子医 理工） Room 5 Oct. 7 (Fri.) 8:00-8:50 J Room 9 Oct. 7 (Fri.) 8:00-8:50 J RUNX genes: Integral component of Fanconi-BRCA pathway In situ Delivery and Production System(iDPS) to Target ML2 ML6 Hypoxia of Solid Cancers with Anaerobic Bifidobacterium 嫌気性ビフィズス菌を用いた固形がんの嫌気的環境を標的とする選択的・持続的抗がん物質の産生系 Chairperson: Rieko Ooki (Natl. Cancer Ctr.) 座長：大木 理恵子（国立がん研究セ・研・難治がん） Chairperson: Shinae Kondoh (Sch. of Life Sci. &d Tech., Tokyo Inst. of Tech.) 座長：近藤 科江（東京工大・院生命理工・生体分子機能） ML2 RUNX genes: Integral component of Fanconi-BRCA pathway Yoshiaki Ito (Cancer Sci. Inst. of Singapore, Natl. Univ. of Singapore) ML6 In situ Delivery and Production System(iDPS) to Target 伊藤 嘉明（Cancer Sci. Inst. of Singapore, Natl. Univ. of Hypoxia of Solid Cancers with Anaerobic Bifidobacterium Singapore） Shun'ichiro Taniguchi (Dept. Comprehensive Cancer Therapy, Shinhsu Univ. Sch. Med.) 嫌気性ビフィズス菌を用いた固形がんの嫌気的環境を標的とする選択 的・持続的抗がん物質の産生系 谷口 俊一郎（信州大・医・包括的がん治療） Room 6 Oct. 7 (Fri.) 8:00-8:50 J Room 10 Oct. 7 (Fri.) 8:00-8:50 J In Memoriam: Alfred G. Knudson Recent Advances in Liquid Biopsy ML7 ML3 —Hereditary cancer & Environmental carcinogenesis— リキッドバイオプシー 最近の動向 Knudson 2 hit 45 周年記念～遺伝性がんと環境発がん～ Chairperson: Hidetoshi Tahara (Dept. of Cell. & Mol. Biol., Hiroshima Univ.) Chairperson: Akira Orimo (Dept. of Path. & Oncology, Juntendo Univ.) 座長：田原 栄俊（広島大・院医歯薬保健・細胞分子生物） 座長：折茂 彰（順天堂大・医・病理・腫瘍） ML7 Recent Advances in Liquid Biopsy ML3 In Memoriam: Alfred G. Knudson‐Hereditary cancer & Masaki Mori (Dept. of Gastroenterological Surg., Grad. Sch. of Med., Environmental carcinogenesis‐ Osaka Univ.) Okio Hino (Dept. of Pathol. & Oncology, Juntendo Univ. Sch. of Med.) リキッドバイオプシー 最近の動向 Knudson 2 hit 45 周年記念～遺伝性がんと環境発がん～ 森 正樹（大阪大・院医・消化器外科） 樋野 興夫（順天堂大・医・病理・腫瘍） Room 7 Oct. 7 (Fri.) 8:00-8:50 J Room 11 Oct. 7 (Fri.) 8:00-8:50 J ASK family kinases in Stress Signaling and Cancer Trends in epigenetic drug discovery for anticancer therapy ML4 ML8 ASK ファミリーによるストレスシグナルとがん がんエピゲノム創薬の潮流 Chairperson: Kohsuke Takeda (Dept. of Cell Reg., Grad. Sch. of Biomed. Sci., Chairperson: Masaya Imoto (Fac. of Sci. & Tech., Keio Univ.) Nagasaki Univ.) 座長：井本 正哉（慶應大・理工） 座長：武田 弘資（長崎大・院医歯薬・細胞制御） ML8 Trends in epigenetic drug discovery for anticancer therapy ML4 ASK family kinases in Stress Signaling and Cancer Minoru Yoshida (RIKEN CSRS) Hidenori Ichijo (Cell Signaling, Grad. Sch. Pharm. Sci., UTokyo) がんエピゲノム創薬の潮流 ASK ファミリーによるストレスシグナルとがん 吉田 稔（理研・環境資源） 一條 秀憲（東京大・院薬・細胞情報） 126 ML-MV INFORMATION Room 13 Oct. 7 (Fri.) 8:00-8:50 J Telomere maintenance system as an anticancer therapeutic MV1 target がん治療標的としてのテロメア維持機構 Chairperson: Ryuzo Ueda (Dept. of Tumor Immunology, Aichi Med. Univ. Sch. of Med.) 座長：上田 龍三（愛知医大・医・ 腫瘍免疫） DAY 1 MV1 Telomere maintenance system as an anticancer therapeutic target Hiroyuki Seimiya (Div. of Mol. Biotherapy, Cancer Chemotherapy Ctr., Japanese Foundation for Cancer Res.) がん治療標的としてのテロメア維持機構 AM PM Posters 清宮 啓之（（公財）がん研・がん化療セ・分子生物治療） LS Room 15 Oct. 7 (Fri.) 8:00-8:50 J Strategic development of combination cancer ML9 immunotherapies 複合免疫療法の戦略的開発 DAY 2 Chairperson: Yataro Daigo (Ctr. Antibody & Vaccine, Inst. Med. Sci., The Univ. of Tokyo) 座長：醍醐 弥太郎（東京大・医科研・抗体・ワクチンセ） ML9 Strategic development of combination cancer AM immunotherapies Kouji Matsushima (Dept. Mol. Preventive Med., Grad. Sch. Med., U Tokyo) LS 複合免疫療法の戦略的開発 PM Posters 松島 綱治（東京大・医・分子予防医学） Room 16 Oct. 7 (Fri.) 8:00-8:50 J DAY 3 Training Junior Scientists in Basic and Translational ML10 Cancer Research in the United States 米国におけるがん基礎研究、臨床への橋渡しと若手研究者の教育 Chairperson: Yasushi Ino (Div. of Innovative Cancer Therapy. Inst. Med. Sci., The Univ. of Tokyo) AM PM Posters 座長：稲生 靖（東京大・医科研・先端医研セ・先端がん治療） LS ML10 Training Junior Scientists in Basic and Translational Cancer Research in the United States Ichiro Nakano (Dept. of Neurosurg., The Univ. of Alabama at Birmingham) 米国におけるがん基礎研究、臨床への橋渡しと若手研究者の教育 中野 伊知郎（Dept. of Neurosurg., The Univ. of Alabama at Birmingham） INDEX Authors Keywords Chairpersons 127 0-1 1-2 JCA-AACR Joint Symposia International Sessions Room 1 Oct. 7 (Fri.) 9:00-11:30 E Room 2 Oct. 7 (Fri.) 9:00-11:30 E Frontiers in genome engineering AACR2 Personalized treatments based on cancer genome profile IS5 ゲノム編集の最前線 Chairpersons: Hiroyuki Mano (Dept. of Cell. Signaling, Grad. Sch. of Med., The Chairpersons: Yasuhiro Yamada (CiRA, Kyoto Univ.) Univ. of Tokyo/Natl. Cancer Ctr. Res. Inst.) Jin-Soo Kim (Ctr. for Genome Engineering, Inst. for Basic Sci.) Marc Ladanyi (Mol. Diagnostics Service, Dept. of Path. & Human 座長：山田 泰広（京都大・ iPS 細胞研究所） Oncology & Pathogenesis Program, Memorial Sloan Kettering Jin-Soo Kim (Ctr. for Genome Engineering, Inst. for Basic Sci.) Cancer Ctr.) Recent advances in genome engineering technology have provided us power- 座長：間野 博行（東京大・院医・細胞情報/国立がん研究セ・研） ful tools to examine various aspects of biology, including cancer biology. Marc Ladanyi (Mol. Diagnostics Service, Dept. of Path. & Human Especially, the CRISPR (clustered regularly interspaced short palindromic Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer repeat) system has been shown to be a versatile experimental platform for Ctr.) genome engineering that uses a guide RNA to target nucleases or transcrip- Characterization of gene expression profiles had been shown useful to stratify tional modifiers to a specific sequence. Similarly, transposon-mediated breast cancer in different prognosis tiers. Additionally, recent advent of genome manipulation is a useful technology for insertional mutagenesis in next-generation sequencers has revealed a number of genetic alterations that both loss-of-function and gain-of-function assays. Furthermore, unique for- play important roles in carcinogenesis. Such information is critical in organ- ward genetic screens can be performed by the combination of such genome izing treatment strategies for a given cancer patient. Thus, high-throughput engineering technologies with stem cell technologies. In this session, we sequencing of tumor DNA for cancer gene panels has attracted a great deal of will learn cutting-edge researches with the latest genome engineering tech- attention in clinics, and the potential utility of “liquid biopsy” is currently nologies and discuss the possible applications of such technologies to cancer under scrutiny. Such momentum is further accelerated by the “Precision reserach. Medicine Initiative” announcement by President Obama in 2015. In this JCA-AACR symposium, such cutting-edge trials are discussed across dif- IS5-1 CRISPR RNA-guided Genome Editing in Human Stem Cells, ferent cancer types for different application. Animals, and Plants Jin-Soo Kim1,2 (1Ctr. for Genome Engineering, Inst. for Basic Sci., 2Dept. AACR2-1 Personalized medicine through cataloging essential growth of Chemistry, Seoul Natl. Univ.) drivers Hiroyuki Mano (Dept. of Cell. Signaling, Grad. Sch. of Med., The IS5-2 CRISPR/Cas9 mediated genome editing in mice Univ. of Tokyo/Natl. Cancer Ctr. Res. Inst.) Masahito Ikawa (Res. Inst. Microbial. Dis, Osaka Univ.) 本質的発がん原因遺伝子の解析がもたらす個別化医療 CRISPR/Cas9 システムを用いたマウスゲノム編集 間野 博行（東京大・院医・細胞情報/国立がん研究セ・研） 伊川 正人（大阪大・微生物研） AACR2-2 Precison Medicine for Advanced Cancer Care IS5-3 When haploid embryonic stem cells met CRISPR-Cas9 Mark A. Rubin (Weill Cornell Med. Coll. & New York-Presbyterian Jinsong Li1,2,3 (1Inst. of Biochemistry & Cell Biol., 2Shanghai Institues for Hosp.) Biological Sciences, 3Chinese Academy of Sciences) AACR2-3 A Novel Genetic Mechanism of Evading Anti-tumor IS5-4 Harnessing endogenous DNA repair pathways for gene editing Immunity In Multiple Human Cancers in human iPSCs. Seishi Ogawa (Pathol. & Tumor Biol., Grad. Sch. of Med., Kyoto Knut Woltjen1,2, Shin-Il Kim1, Tomoko Matsumoto1, Fabian Oceguera- Univ.) Yanez1, Harunobu Kagawa1 (1Ctr. for iPS Cell Res. & Application (CiRA), 2 がんの免疫回避の新たなメカニズムについて Kyoto Univ., Hakubi Ctr. for Advanced Res., Kyoto Univ.) 小川 誠司（京都大・院医・医・腫瘍生物） IS5-5 Transposon mutagenesis identifies genes and evolutionary AACR2-4 The MSK-IMPACT initiative in prospective clinical cancer forces driving gastrointestinal tract tumor progression genomics: the first 10,000 patients Haruna Takeda1,2, Zhubo Wei5, Hideto Koso2,3, Alistair Rust4, Christopher Marc Ladanyi (Mol. Diagnostics Service, Dept. of Pathology & Kuan Yew2, Michiael Mann2,5, Jerrold Ward2, David Adams4, Neal Human Oncology & Pathogenesis Program, Memorial Sloan Copeland2,5, Nancy Jenkins2,5 (11st Dept. of Path., Kanazawa Med. Univ. Kettering Cancer Ctr.) Sch. of Med., 2Div. of Genomics & Genetics, IMCB, 3Inst. of Med. Sci., The Univ. of Tokyo., 4Wellcome Trust Sanger Inst., 5Houston Methodist Res. Inst.) Sleeping Beauty トランスポゾンによる大腸がん形成に関与する 遺伝子の同定 武田 はるな 1,2、Zhubo Wei 5、高祖 秀登 2,3、Alistair Rust 4、 Christopher Kuan Yew 2、Michiael Mann 2,5、Jerrold Ward 2、David Adams 4、Neal Copeland 2,5、Nancy Jenk- ins 2,5（1 金沢医大・医・病理学 I、2 Div. of Genomics & Genet- ics, IMCB、3 東京大・医科研、4 Wellcome Trust Sanger Inst.、 5 Houston Methodist Res.
Load more

Recommended publications
  • ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
    REVIEW published: 07 October 2020 doi: 10.3389/fimmu.2020.576745 ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19 † † Donato Zipeto 1 , Julys da Fonseca Palmeira 2 , Gustavo A. Argañaraz 2 and Enrique R. Argañaraz 2* 1 Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, 2 Laboratory of Molecular Neurovirology, Faculty of Health Science, University of Bras´ılia, Brasilia, Brazil The Coronavirus Disease 2019 (COVID-19) has already caused hundreds of thousands of deaths worldwide in a few months. Cardiovascular disease, hypertension, diabetes and chronic lung disease have been identified as the main COVID-19 comorbidities. Moreover, Edited by: despite similar infection rates between men and women, the most severe course of the Yolande Richard, Institut National de la Sante´ et de la disease is higher in elderly and co-morbid male patients. Therefore, the occurrence of Recherche Me´ dicale (INSERM), specific comorbidities associated with renin–angiotensin system (RAS) imbalance France mediated by the interaction between angiotensin-converting enzyme 2 (ACE2) and Reviewed by: desintegrin and metalloproteinase domain 17 (ADAM17), along with specific genetic Andreas Ludwig, RWTH Aachen University, factors mainly associated with type II transmembrane serine protease (TMPRSS2) Germany expression, could be decisive for the clinical outcome of COVID-19. Indeed, the Elena Ciaglia, — University of Salerno, Italy exacerbated ADAM17 mediated ACE2, TNF-a, and IL-6R secretion emerges as a Rumi Ueha, possible underlying mechanism for the acute inflammatory immune response and the University of Tokyo, Japan activation of the coagulation cascade. Therefore, in this review, we focus on the main *Correspondence: pathophysiological aspects of ACE2, ADAM17, and TMPRSS2 host proteins in COVID- Enrique R.
    [Show full text]
  • Advanced Glycation End Products Evoke Endothelial Cell Damage By
    Ishibashi et al. Cardiovascular Diabetology 2013, 12:125 CARDIO http://www.cardiab.com/content/12/1/125 VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin- like growth factor II receptor Yuji Ishibashi1, Takanori Matsui1, Sayaka Maeda1, Yuichiro Higashimoto2 and Sho-ichi Yamagishi1* Abstract Background: Advanced glycation end products (AGEs) and receptor RAGE interaction play a role in diabetic vascular complications. Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type 2 diabetes. However, the role of DPP-4 in AGE-induced endothelial cell (EC) damage remains unclear. Methods: In this study, we investigated the effects of DPP-4 on reactive oxygen species (ROS) generation and RAGE gene expression in ECs. We further examined whether an inhibitor of DPP-4, linagliptin inhibited AGE-induced soluble DPP-4 production, ROS generation, RAGE, intercellular adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) gene expression in ECs. Results: DPP-4 dose-dependently increased ROS generation and RAGE gene expression in ECs, which were prevented by linagliptin. Mannose 6-phosphate (M6P) and antibodies (Ab) raised against M6P/insulin-like growth factor II receptor (M6P/IGF-IIR) completely blocked the ROS generation in DPP-4-exposed ECs, whereas surface plasmon resonance revealed that DPP-4 bound to M6P/IGF-IIR at the dissociation constant of 3.59 x 10-5 M. AGEs or hydrogen peroxide increased soluble DPP-4 production by ECs, which was prevented by N-acetylcysteine, RAGE-Ab or linagliptin.
    [Show full text]
  • 81969413.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector European Journal of Pharmacology 698 (2013) 74–86 Contents lists available at SciVerse ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Molecular and cellular pharmacology Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats Gisele Giannocco a,b, Kelen C. Oliveira a,b, Renato O. Crajoinas c, Gabriela Venturini c, Thiago A. Salles c, Miriam H. Fonseca-Alaniz c, Rui M.B. Maciel b, Adriana C.C. Girardi c,n a Department of Morphology and Physiology, Faculdade de Medicina do ABC, Santo Andre´,Sao~ Paulo, SP, Brazil b Department of Medicine, Federal University of Sao~ Paulo, Sao~ Paulo, SP, Brazil c University of Sao~ Paulo Medical School, Heart Institute, Laboratory of Genetics and Molecular Cardiology, Avenida Dr. Ene´as de Carvalho Aguiar 44, 101 andar, Bloco II, 05403-900 Sao Paulo, Brazil article info abstract Article history: The purpose of the current study was to test the hypothesis that the dipeptidyl peptidase IV (DPPIV) Received 26 January 2012 inhibitor sitagliptin, which exerts anti-hyperglycemic and anti-hypertensive effects, upregulates GLUT4 Received in revised form translocation, protein levels, and/or mRNA expression in heart and skeletal muscle of spontaneously 19 September 2012 hypertensive rats (SHRs). Ten days of treatment with sitagliptin (40 mg/kg twice daily) decreased Accepted 21 September 2012 plasma DPPIV activity in both young (Y, 5-week-old) and adult (A, 20-week-old) SHRs to similar Available online 7 October 2012 extents (85%).
    [Show full text]
  • Structural Basis for the Sheddase Function of Human Meprin Β Metalloproteinase at the Plasma Membrane
    Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane Joan L. Arolasa, Claudia Broderb, Tamara Jeffersonb, Tibisay Guevaraa, Erwin E. Sterchic, Wolfram Boded, Walter Stöckere, Christoph Becker-Paulyb, and F. Xavier Gomis-Rütha,1 aProteolysis Laboratory, Department of Structural Biology, Molecular Biology Institute of Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona Science Park, E-08028 Barcelona, Spain; bInstitute of Biochemistry, Unit for Degradomics of the Protease Web, University of Kiel, D-24118 Kiel, Germany; cInstitute of Biochemistry and Molecular Medicine, University of Berne, CH-3012 Berne, Switzerland; dArbeitsgruppe Proteinaseforschung, Max-Planck-Institute für Biochemie, D-82152 Planegg-Martinsried, Germany; and eInstitute of Zoology, Cell and Matrix Biology, Johannes Gutenberg-University, D-55128 Mainz, Germany Edited by Brian W. Matthews, University of Oregon, Eugene, OR, and approved August 22, 2012 (received for review June 29, 2012) Ectodomain shedding at the cell surface is a major mechanism to proteolysis” step within the membrane (1). This is the case for the regulate the extracellular and circulatory concentration or the processing of Notch ligand Delta1 and of APP, both carried out by activities of signaling proteins at the plasma membrane. Human γ-secretase after action of an α/β-secretase (11), and for signal- meprin β is a 145-kDa disulfide-linked homodimeric multidomain peptide peptidase, which removes remnants of the secretory pro- type-I membrane metallopeptidase that sheds membrane-bound tein translocation from the endoplasmic membrane (13). cytokines and growth factors, thereby contributing to inflammatory Recently, human meprin β (Mβ) was found to specifically pro- diseases, angiogenesis, and tumor progression.
    [Show full text]
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
    [Show full text]
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Loss of Protease Activity of ADAM15 Abolishes Protective Effects on Plaque Progression in Atherosclerosis
    382 Letters to the Editor Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis Andreas Bültmann, Zhongmin Li, Silvia Wagner, Meinrad Gawaz, Martin Ungerer, Harald Langer, Andreas E. May ⁎⁎, Götz Münch ⁎ Corimmun, Fraunhofer Str. 17, D-82152 Martinsried, Germany Medizinische Klinik III, Eberhard-Karls Universität Tübingen, D-72076 Tübingen, Germany article info For the induction of atherosclerosis, rabbits were fed with Western Article history: type high cholesterol (0.25%) diet for 8 weeks and vascular gene Received 8 August 2011 transfer to the carotid artery was performed as previously described Accepted 13 August 2011 [7]. Available online 9 September 2011 Animals were sacrificed 4 weeks after the adenovirus delivery. Keywords: The left common carotid arteries, aorta and iliac arteries were Atherosclerosis macroscopically prepared for “en face” evaluation of plaque ADAM15 extension and stained with Sudan III. Serial 6-μm-thick cryosections Sheddase were cut and histological assessment of atherosclerosis after Metalloproteinase hematoxylin eosin (HE) and van Gieson (VG)-elastica staining and GFP expression were performed. Immunohistochemical analysis, with anti rabbit RAM 11 antibody (DAKO, Hamburg, Germany) was The A Disintegrin And Metallporteinases (ADAMs) contain a used for macrophages as previously described [12]. metalloprotease-like and a disintegrin-like domain. Currently 40 After vascular gene transfer into the carotid artery, GFP expression different types of ADAM proteins have been identified. ADAM15 is could be detected with AdGFP and also with Ad-ADAM15 and Ad- found in the myocardium [1,2], endothelial cells and in vascular ADAM15 prot neg, which both co-expressed GFP (Fig. 1). Relative atherosclerotic lesions [3].
    [Show full text]
  • Strategies to Target ADAM17 in Disease: from Its Discovery to the Irhom Revolution
    molecules Review Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution Matteo Calligaris 1,2,†, Doretta Cuffaro 2,†, Simone Bonelli 1, Donatella Pia Spanò 3, Armando Rossello 2, Elisa Nuti 2,* and Simone Dario Scilabra 1,* 1 Proteomics Group of Fondazione Ri.MED, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90145 Palermo, Italy; [email protected] (M.C.); [email protected] (S.B.) 2 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; [email protected] (D.C.); [email protected] (A.R.) 3 Università degli Studi di Palermo, STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Viale delle Scienze Ed. 16, 90128 Palermo, Italy; [email protected] * Correspondence: [email protected] (E.N.); [email protected] (S.D.S.) † These authors contributed equally to this work. Abstract: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a number of in vivo models of pathological conditions.
    [Show full text]
  • Proteolytic Cleavage—Mechanisms, Function
    Review Cite This: Chem. Rev. 2018, 118, 1137−1168 pubs.acs.org/CR Proteolytic CleavageMechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification Theo Klein,†,⊥ Ulrich Eckhard,†,§ Antoine Dufour,†,¶ Nestor Solis,† and Christopher M. Overall*,†,‡ † ‡ Life Sciences Institute, Department of Oral Biological and Medical Sciences, and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada ABSTRACT: Proteases enzymatically hydrolyze peptide bonds in substrate proteins, resulting in a widespread, irreversible posttranslational modification of the protein’s structure and biological function. Often regarded as a mere degradative mechanism in destruction of proteins or turnover in maintaining physiological homeostasis, recent research in the field of degradomics has led to the recognition of two main yet unexpected concepts. First, that targeted, limited proteolytic cleavage events by a wide repertoire of proteases are pivotal regulators of most, if not all, physiological and pathological processes. Second, an unexpected in vivo abundance of stable cleaved proteins revealed pervasive, functionally relevant protein processing in normal and diseased tissuefrom 40 to 70% of proteins also occur in vivo as distinct stable proteoforms with undocumented N- or C- termini, meaning these proteoforms are stable functional cleavage products, most with unknown functional implications. In this Review, we discuss the structural biology aspects and mechanisms
    [Show full text]
  • International Session Poster 一般ポスター
    Web 閲覧 International Session Poster 一般ポスター ※本プログラムの演題名・氏名・所属の表記は、ご自身による表記を 優先いたしましたが、統一のため多少変更を加えた部分があります。 KLQSBWZHELQGG KLQSBWZHELQGG International Session Poster 01 ◆ Andrology ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ISP01-01 Withdrawn ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ISP01-02 Results of Assisted Reproductive Treatment in Azoospermic Patients Batmunkh Ganbat（Infertility and Reproductive Center, Mongolian National Center for Maternal and Child Health, Mongolia） ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ISP01-03 Bilateral inguinal hernia diagnosed and treatment on laparoscopic varicocelectomy Erdenebaatar Baljinnyam（Surgical Department, MD, Surgeon of Central Hospital of Arkhangai Aimag, Mongolia） ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
    [Show full text]
  • The Proteolytic Processing of Angiotensin-Converting Enzyme
    Forum REVIEW Shedding the load of hypertension: The proteolytic processing of angiotensin-converting enzyme Mario R W Ehlers, Kerry Gordon, Sylva L U Schwager, Edward D Sturrock A number of membrane proteins are enzymatically cleaved or ‘shed’ shedding has advanced our understanding of the role of ACE from the cell surface, resulting in the modulation of biological events shedding in health and disease. Extensive biochemical and molecular and opening novel pharmaceutical approaches to diverse diseases analysis has helped to elucidate the mechanism of ACE shedding. by targeting shedding. Our focus has been on understanding the These findings point to the potential therapeutic role of targeting shedding of angiotensin-converting enzyme (ACE), an enzyme that shedding in regulating tissue ACE levels in cardiovascular disease. plays a pivotal role in blood pressure regulation. The identification of novel hereditary ACE mutations that result in increased ACE S Afr Med J 2012;102(6):461-464. Shedding of membrane proteins although the most important appear to fall into 2 classes, both of Barely 20 years have elapsed since our first description of membrane which are zinc-dependent proteases: ADAM (a disintegrin and protein shedding as a general phenomenon in biology.1 Also described metalloproteinase) proteases, such as ADAM17 and ADAM10, as ‘membrane protein solubilisation’ but now generally referred to as and MMPs (matrix metalloproteases) (Fig. 1). There is significant ‘ectodomain shedding’, this is a process whereby proteins anchored in interest in finding specific sheddase inhibitors, because of enormous the cell membrane are cleaved and released by specialised proteases pharmaceutical potential in diverse diseases, including auto- called ‘sheddases’.
    [Show full text]